{"id":"W4402540651","doi":"10.1016/j.annonc.2024.08.2242","title":"ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Eisai; Natera; Seagen; Incyte; BeiGene; Clovis Oncology; Novocure; Exelixis; Gilead Sciences; Merck KGaA; Regeneron Pharmaceuticals; Mersana Therapeutics; Karyopharm Therapeutics; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Pembrolizumab; Placebo; Chemotherapy; Adjuvant; Oncology; Radiation therapy; Internal medicine; Cancer; Immunotherapy; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006873789,0.0006027889,0.002948615,0.00111386,0.00007136955,0.00002805037,0.0002905517,0.0002943152,0.001321015],"category_scores_gemma":[0.0001857233,0.0003263175,0.0002224902,0.002327106,0.0002531396,0.0001951549,0.00004576143,0.0005368433,0.00000429485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004731595,"about_ca_system_score_gemma":0.001850669,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00968926,"about_ca_topic_score_gemma":0.005242715,"domain_scores_codex":[0.9959022,0.0003812652,0.001257371,0.00084581,0.0009368917,0.0006764157],"domain_scores_gemma":[0.9963291,0.001686873,0.0006691254,0.0005436756,0.0004337523,0.0003374937],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8029513,0.01074773,0.0304549,0.0001940015,0.003393136,0.0004710508,0.0034547,0.0002341426,0.00006031962,0.000007126687,0.0003332187,0.1476984],"study_design_scores_gemma":[0.8707504,0.1167141,0.005856452,0.0004300776,0.0009595731,0.0000202658,0.0005631922,0.00009459969,0.00155407,0.00000771531,0.002699153,0.0003504017],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871004,0.00271144,0.0001438037,0.000647586,0.0004775432,0.008493023,0.0001299365,0.00007139054,0.0002249417],"genre_scores_gemma":[0.9921136,0.004345422,0.0003711918,0.0005519004,0.0005089582,0.001540183,0.00005502088,0.000115454,0.0003982531],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.147348,"threshold_uncertainty_score":0.9999189,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06538704027016648,"score_gpt":0.4011213257799936,"score_spread":0.3357342855098271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}